Viridian Therapeutics to Join May Investor Conferences

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical firm headquartered in Waltham, Massachusetts, is engaged in the discovery and development of medicines aimed at treating serious and rare diseases. The company's senior management is set to participate in two significant investor conferences in May 2024. The first is the RBCCM Global Healthcare Conference, taking place in New York, NY on Tuesday, May 14, 2024, at 8:30 a.m. ET. The second is the BofA Securities 2024 Health Care Conference, scheduled for Wednesday, May 15, 2024, at 4:35 p.m. PT in Las Vegas, NV.

Viridian Therapeutics will provide live webcasts of both presentations, which can be accessed through the "Events and Presentations" section on the Investors page of their website, viridiantherapeutics.com. Replays of these webcasts will also be available after the events.

The core mission of Viridian Therapeutics is to engineer and develop top-tier medications for patients suffering from severe and rare ailments. Their expertise in antibody discovery and protein engineering has allowed them to create therapeutic candidates targeting well-established disease areas. The company is notably progressing with several candidates in clinical trials to treat thyroid eye disease (TED). Key among these is VRDN-001, currently undergoing two global phase 3 trials named THRIVE and THRIVE-2, to evaluate its efficacy and safety for both active and chronic TED. Viridian aims to establish VRDN-001 as a potential leading intravenous therapy, followed by VRDN-003 as a leading subcutaneous therapy for TED.

Beyond their TED treatments, Viridian is also working on a new portfolio of neonatal Fc receptor (FcRn) inhibitors, specifically VRDN-006 and VRDN-008, which could be developed to address multiple autoimmune diseases. Their innovative approach in these fields underscores their commitment to addressing the needs of patients with serious and rare conditions.